论文部分内容阅读
肾细胞癌(RCC)是恶性度极高的泌尿系统肿瘤,早期病例主要以根治性切除为主,但进展性和转移性RCC的临床治疗效果不佳。随着分子生物学研究的进展,近期RCC靶向治疗不断取得新突破,本文综述进展性透明细胞癌和不同病理分型非透明细胞癌的分子发病基础及近年靶向治疗新进展。
Renal cell carcinoma (RCC) is a very malignant tumor of the urinary system. The early cases are mainly radical resection, but the clinical treatment of progressive and metastatic RCC is ineffective. With the progress of molecular biology research, new breakthroughs have been made in recent RCC targeted therapy. This review summarizes the molecular pathogenesis of progressive clear cell carcinoma and non-clear cell carcinoma of different pathological types and new progress of targeted therapy in recent years.